Fingolimod

Fingolimod
Clinical data
Trade names	Gilenya
AHFS/Drugs.com	Monograph
MedlinePlus	a611006
License data	US DailyMed: Fingolimod;
Pregnancy; category	AU: D; ;
Routes of; administration	By mouth
Drug class	Immunosuppressants
ATC code	L04AE01 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Identifiers
	IUPAC name 2-Amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol;
CAS Number	162359-55-9 ;
PubChem CID	107970;
IUPHAR/BPS	2407;
DrugBank	DB08868 ;
ChemSpider	97087 ;
UNII	3QN8BYN5QF;
KEGG	D10001 ; as HCl: D04187;
ChEBI	CHEBI:63115 ;
ChEMBL	ChEMBL314854 ;
CompTox Dashboard (EPA)	DTXSID40167363 ;
Chemical and physical data
Formula	C19H33NO2
Molar mass	307.478 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;
	InChI InChI=1S/C19H33NO2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22/h9-12,21-22H,2-8,13-16,20H2,1H3 ; Key:KKGQTZUTZRNORY-UHFFFAOYSA-N ;
	(what is this?) (verify)

Fingolimod, sold under the brand name Gilenya, is an immunomodulating medication, used for the treatment of multiple sclerosis.^[3] Fingolimod is a sphingosine-1-phosphate receptor modulator, which sequesters lymphocytes in lymph nodes, preventing them from contributing to an autoimmune reaction. It has been reported to reduce the rate of relapses in relapsing-remitting multiple sclerosis by approximately one-half over a two-year period.^[4]

^ "FINGOLIMOD-TEVA/TE-FINGOLIMOD (Teva Pharma Australia Pty Ltd)". Therapeutic Goods Administration (TGA). 16 February 2023. Retrieved 23 April 2023.
^ "Health product highlights 2021: Annexes of products approved in 2021". Health Canada. 3 August 2022. Retrieved 25 March 2024.
^ Cite error: The named reference AHFS2015 was invoked but never defined (see the help page).
^ Sanford M (August 2014). "Fingolimod: a review of its use in relapsing-remitting multiple sclerosis". Drugs. 74 (12): 1411–33. doi:10.1007/s40265-014-0264-y. PMID 25063048. S2CID 42807019.

[1] "FINGOLIMOD-TEVA/TE-FINGOLIMOD (Teva Pharma Australia Pty Ltd)". Therapeutic Goods Administration (TGA). 16 February 2023. Retrieved 23 April 2023.

[2] "Health product highlights 2021: Annexes of products approved in 2021". Health Canada. 3 August 2022. Retrieved 25 March 2024.

[AHFS2015-3] Cite error: The named reference AHFS2015 was invoked but never defined (see the help page).

[4] Sanford M (August 2014). "Fingolimod: a review of its use in relapsing-remitting multiple sclerosis". Drugs. 74 (12): 1411–33. doi:10.1007/s40265-014-0264-y. PMID 25063048. S2CID 42807019.

[1]

[2]

[3]

[4]